These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 28647170)

  • 1. The complexity and cost of vaccine manufacturing - An overview.
    Plotkin S; Robinson JM; Cunningham G; Iqbal R; Larsen S
    Vaccine; 2017 Jul; 35(33):4064-4071. PubMed ID: 28647170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine provision: Delivering sustained & widespread use.
    Preiss S; Garçon N; Cunningham AL; Strugnell R; Friedland LR
    Vaccine; 2016 Dec; 34(52):6665-6671. PubMed ID: 27884478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.
    Perdue ML; Bright RA
    Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partnering for Vaccine Emerging Markets--Berlin, June 10-11, 2013: balancing vaccine quality, capacity, and cost-of-goods in emerging markets.
    Onraedt A
    Hum Vaccin Immunother; 2013 Sep; 9(9):2022-4. PubMed ID: 23966097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How much does it cost to get a dose of vaccine to the service delivery location? Empirical evidence from Vietnam's Expanded Program on Immunization.
    Mvundura M; Kien VD; Nga NT; Robertson J; Cuong NV; Tung HT; Hong DT; Levin C
    Vaccine; 2014 Feb; 32(7):834-8. PubMed ID: 24370713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers.
    Wahid R; Holt R; Hjorth R; Berlanda Scorza F
    Vaccine; 2016 Oct; 34(45):5430-5435. PubMed ID: 27484011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and successes for the grantees and the Technical Advisory Group of WHO's influenza vaccine technology transfer initiative.
    Grohmann G; Francis DP; Sokhey J; Robertson J
    Vaccine; 2016 Oct; 34(45):5420-5424. PubMed ID: 27506497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The global capacity for manufacturing vaccines. Prospects for competition and collaboration among producers in the next decade.
    Robbins A; Arita I
    Int J Technol Assess Health Care; 1994; 10(1):39-46. PubMed ID: 8157459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manufacturing costs of HPV vaccines for developing countries.
    Clendinen C; Zhang Y; Warburton RN; Light DW
    Vaccine; 2016 Nov; 34(48):5984-5989. PubMed ID: 27771183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccinology capacity building in Europe for innovative platforms serving emerging markets.
    Hendriks J; Holleman M; Hamidi A; Beurret M; Boog C
    Hum Vaccin Immunother; 2013 Apr; 9(4):932-6. PubMed ID: 23563518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive hands-on training for influenza vaccine manufacturing: a WHO-BARDA-BTEC partnership for global workforce development.
    Ruiz J; Gilleskie GL; Brown P; Burnett B; Carbonell RG
    Biochem Mol Biol Educ; 2014; 42(5):414-9. PubMed ID: 25132407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers.
    Chandrasekharan S; Amin T; Kim J; Furrer E; Matterson AC; Schwalbe N; Nguyen A
    Vaccine; 2015 Nov; 33(46):6366-70. PubMed ID: 26368398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost analysis of producing vaccines in developing countries.
    Munira SL; Hendriks JT; Atmosukarto II; Friede MH; Carter LM; Butler JRG; Clements ACA
    Vaccine; 2019 Feb; 37(9):1245-1251. PubMed ID: 30651198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Affordably priced new drugs for poor populations: Approaches for a global solution.
    Mossialos E; Dukes G
    Int J Risk Saf Med; 2001; 14(1):1-29. PubMed ID: 22388482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustainable vaccine manufacturing in low- and middle-Income countries.
    Hayman B; Kumar Suri R; Downham M
    Vaccine; 2022 Nov; 40(50):7288-7304. PubMed ID: 36334966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Casting off vaccine supply charity -- the pace quickens. CVI goal: quality vaccines for all children.
    CVI Forum; 1995 Oct; (10):9-13. PubMed ID: 12290725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining the production costs of antiretroviral drugs.
    Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
    AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.